Omzo vs Willow: Compounded Semaglutide vs Oral GLP-1 Support
Comparing Omzo vs Willow quickly: Omzo centers on personalized, clinician-guided compounded semaglutide starting at $179, while Willow emphasizes an oral GLP-1 program with progress tracking and follow-up starting at $299. Early verdict: choose Omzo if you prioritize compounded weekly injectables and lower entry pricing; choose Willow if you want oral GLP-1 plus structured digital follow-up.
Explore Omzo clinician-guided plans
How Omzo and Willow differ on medication type and regulatory notes
Omzo offers personalized compounded semaglutide and tirzepatide prepared by state-licensed sterile compounding pharmacies. The source states these compounded drugs are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality. Omzo also notes that providers may instead write prescriptions for branded, FDA-approved medications that customers fill at a pharmacy of their choice; Omzo does not sell or ship branded drugs.
Willow positions an oral GLP-1 program. The captured evidence notes that when compounded medications are offered by Willow they are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. The available materials emphasize that medication-specific approval status must be confirmed.
Clinician involvement and care model
Both vendors use licensed clinicians, but they frame care differently. Omzo connects users with licensed U.S. providers who determine eligibility and prescribe either compounded products or prescriptions for branded medications. Omzo describes a clinician-guided plan reviewed by licensed U.S. providers and repeatedly notes that providers make the final determination on prescribing.
Willow is described as a telehealth-first weight management program with a licensed telehealth team and follow-up consultations. The source highlights Willow’s structured progress tracking and follow-up support as central to converting medication efficacy into longer-term outcomes.
Pricing, plan entry, and transparency
Omzo lists semaglutide starting at $179 and tirzepatide starting at $279. The evidence repeatedly warns that pricing, eligibility, pharmacy, state coverage and renewal terms may change, and that medication costs are included in the fees collected by Omzo for compounded programs.
Willow’s captured evidence shows a starting price of 299. The available page capture indicates higher monthly entry pricing for some plans as a potential con. Additional shipping, membership, or cancellation details for Willow were not verified on the captured page.
Follow-up, tracking, and care emphasis
Omzo emphasizes clinician-guided plans with fast, discreet delivery and notes FSA and HSA eligibility for applicable items. The messaging includes patient experience excerpts but clarifies that Omzo is not a medical practice and clinical services are provided by third-party networks of licensed clinicians.
Willow emphasizes progress tracking tools, follow-up consultations, and a structured digital workflow. The source frames Willow as best for users who want structured digital follow-up and behavioral scaffolding alongside medication.
Comparison table at a glance
| Criteria | Omzo | Willow |
|---|---|---|
| Starting price | $179 for semaglutide | $299 |
| Medication type | Compounded semaglutide & tirzepatide; branded prescriptions may be written | Oral GLP-1 program; medication status must be confirmed |
| FDA approval note | Compounded medications are not FDA-approved | Compounded offerings not FDA-approved; approval status must be confirmed |
| Clinician model | Licensed U.S. providers determine eligibility and prescribe | Licensed telehealth team with follow-up consultations |
| Support & tracking | Clinician-guided plans; fast, discreet delivery; FSA & HSA eligible | Progress tracking tools and structured follow-up |
Shipping, pharmacy, and fulfillment notes
Omzo states that compounded medications are prepared and shipped by state-licensed sterile compounding pharmacies and that medication costs for compounded programs are included in Omzo fees; Omzo also says it does not produce or manufacture medications. The evidence for Willow did not capture detailed shipping or fulfillment information.
Risks, limits, and what is not supplied
Both sources include regulatory qualifiers: compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality. Omzo repeatedly cautions that individual results vary and that eligibility, state availability, and renewal terms may change. The captured Willow page did not provide verified shipping, membership, or cancellation details.
See Omzo treatment options and pricing
Quick summary and final guidance on Omzo vs Willow
Omzo focuses on compounded semaglutide and tirzepatide with clinician-guided plans and a lower documented starting price for semaglutide. Willow focuses on an oral GLP-1 program wrapped in progress tracking and follow-up support with a higher documented starting price. Medication approval status, eligibility, and final prescribing remain subject to clinician review for both providers.
Explore Willow oral GLP-1 and tracking
Compare Omzo clinician options now
Learn about Willow follow-up support
Choose Omzo if…
You want clinician-guided access to compounded semaglutide or tirzepatide with documented semaglutide pricing starting at $179, accept that compounded drugs are not FDA-approved, and prefer a clinician network that can also write prescriptions for branded medications to fill elsewhere.
Choose Willow if…
You prefer an oral GLP-1 program with structured progress tracking and follow-up consultations and are willing to consider plans with a higher documented starting price of 299. Medication-specific approval status should be confirmed with Willow clinicians.